Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications

Gynecol Oncol. 2020 Dec;159(3):599-600. doi: 10.1016/j.ygyno.2020.11.002.

Authors

Joshua G Cohen¹, Albert J Chang²

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
² Division of Brachytherapy, Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: AJChang@mednet.ucla.edu.

PMID: 33279016
DOI: 10.1016/j.ygyno.2020.11.002

No abstract available

Publication types

Editorial

MeSH terms

Brachytherapy / adverse effects
Brachytherapy / statistics & numerical data
Brachytherapy / trends
Chemoradiotherapy / adverse effects
Chemoradiotherapy / methods
Chemoradiotherapy / trends
Clinical Trials as Topic
Dose Fractionation, Radiation
Female
Genital Neoplasms, Female / immunology
Genital Neoplasms, Female / mortality
Genital Neoplasms, Female / therapy*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Organ Sparing Treatments / adverse effects
Organ Sparing Treatments / methods
Organ Sparing Treatments / trends*
Radiosurgery / adverse effects
Radiosurgery / methods
Radiosurgery / trends*
SEER Program / statistics & numerical data
Survival Rate
Treatment Outcome

Substances

Immune Checkpoint Inhibitors